Huntington's disease (HD) was first described in 1872 by Dr George Huntington after whom it is named. It is a genetic disease causing persistent neurodegeneration, manifesting in movement, cognitive and psychiatric disturbances that progress over a 10-20 year period, inexorably towards death. » Read more
Contracting is a rapidly growing area in pharmaceutical research and development – the relationship between pharma company and CRO is paramount. Susan McGoldrick at QCTR offers advice on how to build a strong partnership and achieve successful outsourcing. » Read more
From the planning stage through to running a trial and beyond, clinical studies in orphan indications have their own unique problems and particularities. Susan McGoldrick, Fiona Duffy and Crispin Bennett describe the lessons they learned in conducting a trial in Huntington’s disease.» Read more
Just as mountain climbers need to be suitably equipped to negotiate tough terrain, sponsors of studies into orphan diseases need to have robust protocols to guide staff through the trials ahead. Susan McGoldrick focuses on developing a '4x4' protocol for sponsors, regulators and investigators. » Read more
Despite massive sales of drugs for psychiatric and neurodegenerative disorders, there still remains an enormous unmet medical need in these disease areas. Susan McGoldrick at QCTR Limited reports.» Read more
If you are interested in receiving future articles, please email firstname.lastname@example.org with your area of interest.